Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib Phase 2a in Early Alzheimer's Disease
NCT05161715Phase 2Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jan 2022
- Primary completion
- May 2023
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obicetrapib in Alzheimer's disease (AD), sponsored by NewAmsterdam Pharma. Primary endpoints: Mean Percent Change in Apolipoprotein A-I in Cerebrospinal Fluid at 24 weeks, Mean Percent Change in Apolipoprotein A-I in Plasma at 24 weeks and 5 more. Started Jan 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05161715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05161715.